Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medical Imaging
  4. Fast Track Articles
  5. Fast Track Article
image of A Comparative Study on CT-guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients
file format pdf download PDF

Abstract

Objective:

The study aimed to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.

Methods:

We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG; n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG; n=40, treated solely with targeted therapy).

Results:

The Overall Response Rate (ORR) and Disease Control Rate (DCR) in the OG group (70.00%, 95.00%) were significantly higher than those in the CG group (57.50%, 87.50%). After 6 weeks of treatment, the OG group had significantly lower levels of SCC, CEA, and CA125, higher CD4+ levels, and lower CD8+ levels, compared to the CG group. The 24-month follow-up survival rate of the OG group (47.50%) was significantly higher than that of the CG group (27.50%).

Conclusion:

CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.

© 2024 The Author(s). Published by Bentham Science.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056311827241211092432
2025-01-02
2025-01-29

  • From This Site

    /content/journals/cmir/10.2174/0115734056311827241211092432
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmir/10.2174/0115734056311827241211092432/e15734056311827.html?itemId=/content/journals/cmir/10.2174/0115734056311827241211092432&mimeType=html&fmt=ahah

References

  1. Ahmed T. Vial M.R. Ost D. Stewart J. Hasan M.A. Grosu H.B. Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series. Lung Cancer 2018 122 220 223 10.1016/j.lungcan.2018.06.024 30032836
    [Google Scholar]
  2. RAFEi H. El-Bahesh E. FiNiANOS A.N.T.O.I.N.E. NASSEREDDiNE S.A.M.A.H. Tabbara I. Immune-based therapies for non-small cell lung cancer. Anticancer Res. 2017 37 2 377 388 10.21873/anticanres.11330 28179283
    [Google Scholar]
  3. Arrieta O. Barrón Z.Z.L. Cardona A.F. Carmona A. Mejia L.M. Ramucirumab in the treatment of non-small cell lung cancer. Expert Opin. Drug Saf. 2017 16 5 637 644 10.1080/14740338.2017.1313226 28395526
    [Google Scholar]
  4. Ginn L. Shi L. La Montagna M. Garofalo M. LncRNAs in non-small-cell lung cancer. Noncoding RNA 2020 6 3 25 10.3390/ncrna6030025 32629922
    [Google Scholar]
  5. Wang X. Zhang G. Cheng Z. Dai L. Jia L. Jing X. Wang H. Zhang R. Liu M. Jiang T. Yang Y. Yang M. Knockdown of LncRNA-XIST suppresses proliferation and TGF-β1-induced EMT in NSCLC through the Notch-1 pathway by regulation of miR-137. Genet. Test. Mol. Biomarkers 2018 22 6 333 342 10.1089/gtmb.2018.0026 29812958
    [Google Scholar]
  6. Chen P. Liu Y. Wen Y. Zhou C. Non‐small cell lung cancer in China. Cancer Commun. 2022 42 10 937 970 10.1002/cac2.12359 36075878
    [Google Scholar]
  7. Rath B. Plangger A. Hamilton G. Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer. Cancer Drug Resist. 2020 3 2 171 178 10.20517/cdr.2019.85 35582610
    [Google Scholar]
  8. Schabath M.B. Cote M.L. Cancer progress and priorities: Lung cancer. Cancer Epidemiol. Biomarkers Prev. 2019 28 10 1563 1579 10.1158/1055‑9965.EPI‑19‑0221 31575553
    [Google Scholar]
  9. Romaszko A.M. Doboszyńska A. Multiple primary lung cancer: A literature review. Adv. Clin. Exp. Med. 2018 27 5 725 730 10.17219/acem/68631 29790681
    [Google Scholar]
  10. Jones G.S. Baldwin D.R. Recent advances in the management of lung cancer. Clin. Med. 2018 18 2 s41 s46 10.7861/clinmedicine.18‑2‑s41 29700092
    [Google Scholar]
  11. Nooreldeen R. Bach H. Current and future development in lung cancer diagnosis. Int. J. Mol. Sci. 2021 22 16 8661 10.3390/ijms22168661 34445366
    [Google Scholar]
  12. Tan A.C. Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC). Thorac. Cancer 2020 11 3 511 518 10.1111/1759‑7714.13328 31989769
    [Google Scholar]
  13. Golding B. Luu A. Jones R. Petit V.A.M. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol. Cancer 2018 17 1 52 10.1186/s12943‑018‑0810‑4 29455675
    [Google Scholar]
  14. Zhang K.R. Zhang Y.F. Lei H.M. Tang Y.B. Ma C.S. Lv Q.M. Wang S.Y. Lu L.M. Shen Y. Chen H.Z. Zhu L. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Sci. Transl. Med. 2021 13 614 eabg6428 10.1126/scitranslmed.abg6428 34613810
    [Google Scholar]
  15. Chockalingam A. Konstantinidis M. Koo B. Moon J.T. Tran A. Nourouzpour S. Lawson E. Fox K. Habibollahi P. Odisio B. Loya M. Bassir A. Nezami N. Surgical resection, radiotherapy and percutaneous thermal ablation for treatment of stage 1 non-small cell lung cancer: Protocol for a systematic review and network meta-analysis. BMJ Open 2022 12 6 e057638 10.1136/bmjopen‑2021‑057638 35710245
    [Google Scholar]
  16. Rangamuwa K. Leong T. Weeden C. Labat A.M.L. Bozinovski S. Christie M. John T. Antippa P. Irving L. Steinfort D. Thermal ablation in non-small cell lung cancer: A review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl. Lung Cancer Res. 2021 10 6 2842 2857 10.21037/tlcr‑20‑1075 34295682
    [Google Scholar]
  17. Li J. Zhong X. Zhao Y. Shen J. Pilapong C. Xiao Z. Polyphenols as lung cancer chemopreventive agents by targeting microRNAs. Molecules 2022 27 18 5903 10.3390/molecules27185903 36144639
    [Google Scholar]
  18. Drosten M. Barbacid M. Targeting KRAS mutant lung cancer: Light at the end of the tunnel. Mol. Oncol. 2022 16 5 1057 1071 10.1002/1878‑0261.13168 34951114
    [Google Scholar]
  19. Ernani V. Stinchcombe T.E. Management of brain metastases in non–small-cell lung cancer. J. Oncol. Pract. 2019 15 11 563 570 10.1200/JOP.19.00357 31715122
    [Google Scholar]
  20. Ye X. Wei Z. Yang X. Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation. J. Cancer Res. Ther. 2020 16 5 1191 1195 10.4103/jcrt.JCRT_798_20 33004770
    [Google Scholar]
  21. Miller L.J. Douglas C. McCullough F.S. Stanworth S.J. Calder P.C. Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: A systematic review of randomised controlled trials. Clin. Nutr. 2022 41 10 2135 2146 10.1016/j.clnu.2022.07.039 36067585
    [Google Scholar]
  22. Hattori S. Okauchi S. Sasatani Y. Ohara G. Miyazaki K. Sato S. Kodama T. Shiozawa T. Satoh H. Hizawa N. Discontinuation of immune checkpoint inhibitor and survival in patients with non-small-cell lung cancer without a driver gene mutation. Anticancer Res. 2022 42 9 4589 4595 10.21873/anticanres.15962 36039463
    [Google Scholar]
/content/journals/cmir/10.2174/0115734056311827241211092432
Loading
A Comparative Study on CT-guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients
Bentham Science Publishers , e15734056311827; https://doi.org/10.2174/0115734056311827241211092432
/content/journals/cmir/10.2174/0115734056311827241211092432
/content/journals/cmir/10.2174/0115734056311827241211092432
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Lung cancer ; Survival time ; Radiofrequency ablation ; Clinical efficacy ; Targeted therapy ; Safety ; Immune response

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test